Novavax Vaccine OK'd After Political Interference: JAMA
FDA’s full approval last month of Novavax’s Covid-19 vaccine is raising alarms due to its unusual delay and politically entangled review process that diverged from long-established regulatory norms, according to former agency and HHS officials writing in a 6/9 JAMA viewpoint article.
The vaccine had a 4/1 user fee review action target date but that deadline came and went (see earlier story). Although FDA reviewers had reportedly recommended approval before the deadline, officials in the FDA Commissioner’s Office put the decision on hold, the article notes. The delay, according to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., reflected the department’s shifting focus toward combination vaccines that protect against multiple viruses — comments that caught many observers off guard, as such considerations fall outside the legal criteria FDA uses when evaluating product safety and efficacy.
The Novavax vaccine delay also coincided with a notable shift in policy — FDA now is requiring placebo-controlled trials for all future Covid-19 boosters in healthy adults under 65, which is a departure from the streamlined approval process used in previous years that relied on immune response data rather than new clinical outcomes trials, the authors note. That policy change, disclosed in a journal article rather than through the usual guidance development process, has drawn criticism for bypassing the public input and transparency typically required for such major regulatory shifts.
The authors say the Novavax episode reflects deeper concerns about political interference in FDA’s scientific review process. Historically, approval decisions have been delegated to career scientists in the agency’s product-specific review Centers. Political appointees, including those in the Commissioner’s Office or at HHS, rarely intervene in those decisions. However, under the current administration, at least one political appointee was embedded in CBER and played a role in the Novavax review, they note.
That level of involvement, once highly unusual, has prompted alarm from the authors, warning that undermining the independence of FDA reviewers could jeopardize public trust and introduce legal vulnerabilities, especially if decisions appear to be driven by political priorities rather than scientific evidence. “The FDA’s procedures are what give it credibility as a global gold standard,” write the authors. “Deviations from that process — especially if they become normalized — threaten both public confidence and biomedical innovation.”
It remains to be seen whether the Novavax review represents a one-time anomaly or a broader change in regulatory practice. But the authors of the JAMA piece warn that if the latter is true, the implications could be serious.“Unpredictable approval processes could discourage investment in new vaccines and treatments,” they write. “And ultimately, it’s patients who stand to lose the most.”